

Aurealis Pharma to Present at Sachs Associates 17th Annual Biotech in Europe Forum Basel, September 26-27th 2017

Basel Switzerland, Kuopio Finland – September 24th 2017.

Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CSO Thomas Wirth and CMO Dirk Weber along with Board Directors Silvio Inderbitzin and Roger Meier will attend the 17th Annual Biotech in Europe Forum held in Congress Center Basel, Switzerland on September 26-27th 2017.

CSO and Chairman Thomas Wirth will present the company and its recent achievements on Tuesday September 26th 2017 at 10:10 am (Presentation Track B).

“We are pleased to attend and present our technology platform and products. The idea of putting two or more medicines together to treat a single disease is a cornerstone of modern medicine. The aim of combination therapies is to bring synergies with a hopefully positive impact on therapeutic outcome. We are happy to see the progress of our two programs and the interests it raises. Our technology truly enables targeting multiple mechanism of actions as a single active ingredient” said Dr. Thomas Wirth.

“Non-healing, chronic wounds as well as many malignant cancers have a lot in common with regards to inflammation and escape mechanisms active in both diseases. We are very pleased to have development candidates derived from our technology to address the high unmet medical need in both diseases and to bring AUP-16 as treatment for chronic wounds into clinical development with a first-in-human clinical study planned to be initiated during next year” continued Dr. Dirk Weber.

About Aurealis Pharma

Aurealis Pharma is a Basel, Switzerland and Kuopio, Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to re-educate the distorted host immune microenvironment in chronic inflammation and cancer to its proper state. Company’s technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue effectively, safely and economically to address the unmet medical need in chronic wounds and cancer.

About the 17th Annual Biotech in Europe Forum:

The forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science industry. The Forum draws together an exciting cross-section



AUREALIS PHARMA

Hochbergerstrasse 60C

CH-4057 Basel

Switzerland

www.aurealispharma.com

Microkatu 1

FI-70210 Kuopio

Finland

of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives.

For more information:

Juha Yrjänheikki, CEO

Aurealis Pharma AG

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)



AUREALIS PHARMA
Hochbergerstrasse 60C
CH-4057 Basel
Switzerland
www.aurealispharma.com

Microkatu 1
FI-70210 Kuopio
Finland